Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 326-333, 2007. First published January 2, 2007; 10.1373/clinchem.2006.076448
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow 076448.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.076448v1
53/2/326    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Obeid, R.
Right arrow Articles by Herrmann, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Obeid, R.
Right arrow Articles by Herrmann, W.
Related Collections
Right arrow General Clinical Chemistry
(Clinical Chemistry. 2007;53:326-333.)
© 2007 American Association for Clinical Chemistry, Inc.

General Clinical Chemistry

Biomarkers of Folate and Vitamin B12 Are Related in Blood and Cerebrospinal Fluid

Rima Obeid1, Panagiotis Kostopoulos2, Jean-Pierre Knapp1, Mariz Kasoha1, George Becker2,1, Klaus Fassbender2 and Wolfgang Herrmann1,a

Departments of1 Clinical Chemistry and Laboratory Medicine and 2 Neurology, Faculty of Medicine, University Hospital of Saarland, Homburg/Saar, Germany.

aAddress correspondence to this author at: Department of Clinical Chemistry and Laboratory Medicine, University Hospital of the Saarland, Kirrberger Straße, Gebäude 57, 66421 Homburg, Germany. Fax 49-6841-1630703; e-mail kchwher{at}uniklinikum-saarland.de.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Background: B-vitamins (folate, B12) are important micronutrients for brain function and essential cofactors for homocysteine (HCY) metabolism. Increased HCY has been related to neurological and psychiatric disorders. We studied the role of the B-vitamins in HCY metabolism in the brain.

Methods: We studied blood and cerebrospinal fluid (CSF) samples from 72 patients who underwent lumbar puncture. We measured HCY, methylmalonic acid (MMA), and cystathionine by gas chromatography-mass spectrometry; S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) by liquid chromatography-tandem mass spectrometry; and the B-vitamins by HPLC or immunoassays.

Results: Concentrations were lower in CSF than serum or plasma for HCY (0.09 vs 9.4 µmol/L), SAH (13.2 vs 16.8 nmol/L), cystathionine (54 vs 329 nmol/L), and holotranscobalamin (16 vs 63 pmol/L), whereas concentrations in CSF were higher for MMA (359 vs 186 nmol/L) and SAM (270 vs 113 nmol/L; all P <0.05). CSF concentrations of HCY correlated significantly with CSF folate (r = –0.46), CSF SAH (r = 0.48), CSF-albumin (r = 0.31), and age (r = 0.32). Aging was also associated with lower concentrations of CSF-folate and higher CSF-SAH. The relationship between serum and CSF folate depended on serum folate: the correlation (r) of serum and CSF-folate was 0.69 at serum folate <15.7 nmol/L. CSF concentrations of MMA and holotranscobalamin were not significantly correlated.

Conclusions: CSF and serum/plasma concentrations of vitamin biomarkers are significantly correlated. Older age is associated with higher CSF-HCY and CSF-SAH and lower CSF-folate. These metabolic alterations may be important indicators of low folate status, hyperhomocysteinemia, and neurodegenerative diseases.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Folate and cobalamin (vitamin B12) are important micronutrients for brain function (1). Both vitamins are required for the catabolism of the sulfur-containing amino acid homocysteine (HCY).2 Methylcobalamin is the cofactor for methionine synthase, the enzyme that mediates HCY remethylation to methionine. HCY metabolism in the brain differs slightly from that in the liver. The alternative remethylation pathway that is mediated by betaine-HCY methyl transferase seems to be absent in the brain (2). The transsulfuration of HCY in the brain has not been well studied, but the presence of cystathionine ß-synthase has been confirmed by several investigators (3).

Methionine, the methylation product of HCY, is a major source of S-adenosylmethionine (SAM) in the brain (1). Folate and vitamin B12 are important cofactors for SAM production in the brain (4). Folate and/or cobalamin deficiency can cause increased concentrations of HCY and disturbed methylation status. The importance of the transmethylation pathway in the central nervous system has been outlined (5)(6). SAM is the most important methyl donor in the brain. Disturbed methylation has been implicated in the etiology of psychiatric and neurologic illness (5)(6). Biological methylation by SAM is involved in the integrity and maintenance of myelin, synthesis and inactivation of neurotransmitters, and DNA and RNA synthesis and methylation.

Recent studies demonstrated that increased plasma HCY concentration is a risk factor for several disorders of the central nervous system (7)(8)(9). A causal role for HCY in neuronal damage has been shown by numerous in vitro and in vivo studies. Deficiencies of folate and cobalamin are common (10)(11), especially in patients with neurological and neuropsychiatric disorders (12), suggesting a causal role for B-vitamin deficiency in neuronal damage, either directly or via increasing HCY concentrations. The relationship between HCY and brain function seems stronger in observational (13) than in intervention studies (14)(15)(16), a finding that could be related to the inability of the central nervous system to regenerate.

Little is known about the influence of B-vitamin status on HCY metabolism and the methylation capacity of the brain. We investigated the role of folate and cobalamin as determinants of HCY concentrations in the cerebrospinal fluid (CSF) and the relationship between blood and CSF concentrations of HCY, cystathionine (Cys), holotranscobalamin (holoTC), and methylmalonic acid (MMA).


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
patients and specimens
Patients were recruited from the Department of Neurology, Saarland University Hospital, Germany, during April 2002 and April 2004. The study included 72 patients (41 females, 31 males). Exclusion criteria included liver dysfunction, alcoholism, treatment with L-dopa or anticonvulsants, major depression, brain tumor, multiple sclerosis, or peripheral neuropathy. CSF samples contaminated with peripheral blood or hemoglobin or with cell count >5 cells/µL were excluded from this study.

Nonfasting blood samples were collected from all patients. Serum and EDTA plasma were available. CSF samples were collected during clinically indicated lumbar punctures. Blood and CSF samples were collected within 24 h of each other. Blood and CSF samples were centrifuged within 30 min of collection, and several aliquots were prepared and stored at –80 °C until analysis. Aliquots of the EDTA-plasma and CSF were immediately deproteinized with perchloric acid (100 g/L). These samples were stored at –80 °C and were used for SAM and S-adenosylhomocysteine (SAH) assays. An aliquot of the CSF was used for determining cell count and protein and glucose concentrations. The study was approved by the Ethics Committee at the Saarland University Hospital, and written informed consent was obtained from all patients.

analytical methods
Concentrations of HCY, Cys, and MMA were measured in serum and CSF samples with gas chromatography mass spectrometry as described elsewhere (17). Day-to-day imprecision (CV) for HCY was <5% in serum (at 8.0 and 16.0 µmol/L) and <10% in CSF (at 0.30 µmol/L). The CV for MMA was <6% in serum and CSF (at 290 and 540 nmol/L, respectively), and for Cys, it was <8% in serum (at 300 nmol/L) and <10% in CSF (at 60 nmol/L). The recovery of the 3 metabolites in CSF was 99% to 107% (see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol53/issue2 ). In-house prepared pool serum and pool CSF were run each time with the study sample and were used to calculate the assay CV. Concentrations of SAM and SAH were measured with a slightly modified liquid chromatography-tandem mass spectrometry method according to Gellekink et al. (18). CVs for SAM and SAH assays were 4.8% and 8%, respectively at 103 nmol/L for SAM and 15.6 nmol/L for SAH.

Concentrations of vitamin B12 and folate were measured with a chemiluminescence immunoassay (ADVIA Centaur System, Bayer), plasma vitamin B6 (pyridoxal-5-phosphate) with HPLC connected to a fluorescence detector (with reagents from Immundiagnostik), and serum and CSF holoTC with RIA (Axis-Shield). The CVs for the holoTC assay were 6% and 8% at 37 and 95 pmol/L, respectively. Serum concentrations of cholesterol and triglycerides were measured by enzymatic colorimetric tests (Roche Diagnostics), and HDL by an enzymatic homogeneous assay (Roche Diagnostics). LDL was calculated from total cholesterol, triglycerides, and HDL according to the Friedewald equation. Serum creatinine concentrations were measured in serum with a kinetic colorimetric assay (Roche Diagnostics), and quantitative glucose was measured by enzymatic ultraviolet test (hexokinase method). Albumin concentration was measured by nephelometry with specific antibodies (DADE Behring). Cell counts and routine variable were measured immediately, and concentrations of B vitamins and metabolites were measured within 6 months of sample collection.

statistical analyses
Data analyses were performed with SPSS (version 12). All variables were skewed and therefore were log-transformed to approach gaussian distribution before application of parametric tests. We used the paired t-test to compare means of the log-transformed variables in blood and CSF and the 1-way ANOVA test for multiple comparisons. The post hoc Tamhane-T test was performed to identify the significantly different group means when the ANOVA test was significant. Correlations between variables were examined by Spearman Rho test. All tests were 2-sided; P values <0.05 were considered statistically significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The main characteristics of the study population are summarized in Table 2 in the online Data Supplement. Concentrations of HCY and related biomarkers in blood and CSF are presented in Table 1 . Concentrations of HCY, Cys, and MMA in the CSF were comparable to those found in previous studies (19)(20). Concentrations of HCY in serum were ~119-fold higher than concentrations in the CSF. In contrast, concentrations of MMA were higher in the CSF than in serum (Table 1 ). Concentrations of SAH were significantly lower in the CSF than in plasma (13.2 vs 16.8 nmol/L, respectively). Furthermore, CSF concentrations of SAM were significantly higher than plasma concentrations (270 vs 113 nmol/L, respectively). The SAM:SAH ratio was markedly higher in CSF than in plasma.


View this table:
[in this window]
[in a new window]

  		Table 1. Concentrations of the biomarkers in serum/plasma and CSF.1

Concentrations of folate were only slightly higher in the CSF than in serum (Table 1Up ), and concentrations of holoTC were lower in the CSF than in serum (Table 1Up ). Total cobalamin and vitamin B6 were not detectable in CSF samples.

CSF markers related to serum concentrations of folate, HCY, and MMA are shown in Table 2 . Serum concentrations of folate ≤25 nmol/L were associated with lower concentrations of CSF folate (P = 0.002) and higher concentrations of CSF-HCY (P = 0.010). Furthermore, serum concentrations of HCY >10.8 µmol/L were associated with lower concentrations of CSF folate (P = 0.004) and older age (P <0.001). CSF concentrations of HCY tended to increase with increasing serum HCY (Table 2 ). Higher concentrations of CSF-HCY and CSF-MMA were found with serum MMA concentrations >217 nmol/L. Neither CSF-SAH nor CSF-SAM concentrations changed with increasing serum folate, serum HCY, or serum MMA (Table 2 ).


View this table:
[in this window]
[in a new window]

  		Table 2. Concentrations [geometric mean (SD)] of the biomarkers in CSF samples according to serum concentrations of folate, HCY, and MMA.

The relationship between serum and CSF folate seemed to be dependent on serum concentrations of folate. Concentrations of CSF folate were higher than those of serum folate in the lowest tertile of serum folate (5.4–15.6 nmol/L), whereas in the highest tertile of serum folate, CSF folate was lower than serum folate (Fig. 1 ). The correlation between serum and CSF folate was strong in the lowest tertile (5.4–15.6 nmol/L) of serum folate (r = 0.69; P = 0.002). In contrast, no significant correlation was found between serum and CSF folate in the higher range of serum folate.


Figure 1
View larger version (17K):
[in this window]
[in a new window]

  		Figure 1. Concentrations of serum and CSF folate according to tertiles of serum folate.

P values are according to ANOVA and Tamhane-T tests.

Concentrations of HCY in the CSF correlated to CSF-folate (r = –0.46; P = 0.002; Fig. 2A ), CSF-Cys (r = 0.57; P <0.001; Fig. 2B ), and CSF-albumin (r = 0.31; P = 0.045; Fig. 2C ). CSF concentrations of HCY correlated to those of SAH (r = 0.48 and r = 0.68) after adjusting for age. Furthermore, serum and CSF concentrations of HCY correlated significantly (r = 0.34; P = 0.014). The last correlation was stronger after adjusting for age (r = 0.70; P <0.001), CSF folate (r = 0.62; P <0.001), or serum folate (r = 0.69; P <0.001). No significant association between CSF-HCY and vitamin B12 markers in the CSF (holoTC, MMA) was observed. CSF concentrations of SAH and HCY increased with increasing age (r = 0.48 and r = 0.32, respectively; P <0.001). Other correlations between SAH, SAM, and blood vitamin concentrations were not significant. The most important significant correlations between age and CSF markers and between serum and CSF markers are presented in Table 3 .


Figure 2
View larger version (14K):
[in this window]
[in a new window]

  		Figure 2. The correlation between concentrations of CSF-HCY and CSF-folate (A), CSF-Cys (B), and CSF-albumin (C).

The correlation coefficients are according to Spearman rho test. One HCY outlier was omitted from this figure.


View this table:
[in this window]
[in a new window]

  		Table 3. Significant correlations between concentrations of vitamin markers in blood and CSF.1


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Hyperhomocysteinemia, or B-vitamin deficiency, is a risk factor for neurological and psychiatric diseases. Little is known about HCY transport and metabolism in human brain. The role of B-vitamins in HCY metabolism and the methylation status in the brain is of particular importance because in some neurological diseases, brain and CSF HCY and SAH concentrations are increased and SAM concentration is decreased (21)(22).

We observed a weak association between CSF and serum concentrations of HCY (r = 0.34; P = 0.014), and this correlation remained significant after adjustment for age, CSF folate, or serum folate. These results suggest that increased concentrations of HCY in the circulation may lead to increased HCY concentration in the CSF, an effect that could be related to HCY exchange between the circulation and the CSF. In contrast to our current results, a previous study found no correlation between plasma and CSF concentrations of HCY in patients with multiple sclerosis (23). These different findings may be attributable to differences in the underlying diseases of the study groups.

Concentrations of methionine in CSF are low (~3–4 µmol/L, that is, 1/10 that in the plasma). Therefore, because HCY is produced from methionine, low HCY concentrations may be expected in CSF, but the detected amount of CSF-HCY is 0.96% (mean value) of that in the plasma. Possible explanations for the unexpectedly low CSF HCY values include lower flow of methionine into HCY in the brain compared with the liver or export of excess brain HCY to the plasma. The possibility of HCY exchange between the brain and the circulation is supported by findings from cystathionine ß-synthase-deficient patients (24). In case of excess HCY in the plasma (homocysteinuria), an increased amount of HCY has been detected in CSF (24). Moreover, decreasing plasma HCY by means of betaine caused a reduction in CSF-HCY (24), suggesting that in addition to HCY production within the brain, plasma and CSF HCY may be exchanged via a bidirectional receptor. In our study, in which only 10% of patients had plasma HCY >16.2 µmol/L, CSF-HCY was not related to the integrity of the blood–brain barrier (i.e., the ratio of CSF albumin:serum albumin; data not shown).

We showed that lower concentrations of serum folate may predict higher concentrations of HCY in CSF (Table 2Up ). Folate is transported into the brain across the blood–brain barrier via specific transporters. Concentrations of folate are generally higher in the CSF than in the blood (25). Moreover, because of the active transport of folate by the choroid plexus, CSF concentrations of folate remained stable when plasma folate was >45 nmol/L (26), data that correspond well with our results. Moreover, our data further suggest that CSF folate is relatively conserved and is not subject to strong fluctuations when serum concentrations change. As can be inferred from Fig. 1Up , differences between serum folate of ~19 nmol/L were associated with only a small difference in CSF folate (~4 nmol/L). These results also indicate that the transport of folate into the brain is subject to a rate-limiting step.

Low folate status is common in elderly people and in neurological and psychogeriatric patients. Folate deficiency has been related to several age-related neurological diseases (27). Low CSF folate can cause disturbances in the metabolism of pteridins and monoamins (28) or severe neurological symptoms(29). In accordance with previous studies, older age was associated with a higher concentration of CSF-HCY and a lower CSF-folate (30)(31), an association attributable to increased plasma concentrations of HCY or reduced concentrations of serum folate with age. Therefore, depletion of CSF folate and increment of CSF-HCY may explain the association between low folate status and hyperhomocysteinemia and neurodegenerative diseases.

Cobalamin deficiency is very common in patients with dementia and those with Alzheimer disease. These results stress the importance of vitamin B12 for brain function. Cobalamin is actively transported into the brain via a specific receptor. Cobalamin is mainly (60%–99%) bound to the binding protein transcobalamin in the central nervous system (32). Cultured astrocytes from human brain secrete functionally active transcobalamin that can facilitate the uptake of cobalamin from the circulation (33). Blood cobalamin content seems to be the major determinant of brain and CSF cobalamin (34). We demonstrated that concentrations of holoTC in the CSF correlated to serum holoTC and cobalamin. Therefore, cobalamin deficiency may cause lower cobalamin content in the brain and thereby neuronal damage. In line with these results, CSF concentrations of cobalamin were lower in cobalamin-deficient than nondeficient persons (35).

In contrast to the situation in serum, our data do not support a major role for brain cobalamin as a determinant for HCY concentrations in the CSF, possibly because plasma HCY mostly reflects liver metabolism and can be modified by vitamin B12 status in addition to variations in renal function. We found higher concentrations of holoTC in serum than in CSF (Table 1Up ), but the holoTC:albumin ratio was higher in CSF than in plasma (65 x 10–2 vs 1.43 x 10–2; Table 1Up ). Compared with other proteins, holoTC seems to be present in higher amounts in the brain than in the circulation. Therefore, higher holoTC concentrations in the brain than in the blood may protect the brain from strong variations in circulating cobalamin.

We have shown that individuals with higher serum concentrations of MMA had higher concentrations of CSF HCY (Table 2Up ), suggesting that low vitamin B12 status (indicated by higher serum concentration of MMA) can cause neuronal damage at least partly, by increasing HCY in the brain. Because vitamin B12 has a limited role in determining concentrations of MMA in CSF (Table 3Up ), increased MMA in CSF could be related to increased substrate rather than to low B12 status or methyl malonyl-CoA mutase activity.

Branched chain amino acids, fatty acids, and methionine are important substrates for MMA production. Branched chain amino acids are important precursors for neurotransmitters synthesis in the brain, and branched chain amino acid aminotransferase concentrations are higher in the brain than the liver (36). The brain tends to decrease in size and weight at older age, and the synthesis of neurotransmitters may be reduced. Moreover, there is some selective loss in the number and size of neurons and a reduction in CSF flow (37). These factors might also explain the negative relationship between age and CSF-MMA in our study and a previous one (30).

SAM and SAH concentrations in the CSF may reflect the methylation status of the brain and thus be markers in some neurological diseases. The SAM:SAH ratio in the CSF indicates the methylation status in other brain regions (38). We found that CSF concentrations of SAH increased with increasing age, possibly because of slower removal of this conversion of product. Another possible cause is increased HCY to SAH, which is supported by the strong positive correlation between CSF-HCY and CSF-SAH (r = 0.68; P <0.001 after adjusting for age). Concentrations of CSF-SAM were not related to CSF-SAH or to any vitamin marker tested in this study, with the exception of plasma SAM and SAH. Brain SAM may also be influenced by turnover and exchange with plasma SAM and plasma methionine.

Concentrations of plasma and CSF SAM and SAH in our study were comparable with those from other studies (39)(40). SAM and SAH are unstable, and preanalytical conditions are important for the assessment of these 2 compounds. Moreover, our current results cannot be compared with those of older studies because of variations in the analytical methods and units used.

In summary, our current study demonstrated that age and serum concentrations of HCY and folate are significant determinants of CSF-HCY. A significant role for vitamin B12 status as a determinant of CSF-HCY was reflected by MMA in serum but not in CSF. Our results suggest that improved folate and vitamin B12 status may be associated with higher concentrations of CSF vitamin and lower concentrations of CSF-HCY. Future studies should investigate the clinical implications of these metabolic consequences.


   Acknowledgments
 
The study was supported by a grant from Karl and Lore Stiftung and by the Alexander von Humboldt Foundation.


   Footnotes
 
1 Dr. Becker died in 2003.

2 Nonstandard abbreviations: HCY, homocysteine; SAM, S-adenosylmethionine; CSF, cerebrospinal fluid; Cys, cystathionine; holoTC, holotranscobalamin; MMA, methylmalonic acid; SAH, S-adenosylhomocysteine.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull 1999;55:669-682.[Abstract/Free Full Text]
  2. McKeever MP, Weir DG, Molloy A, Scott JM. Betaine-homocysteine methyltransferase: organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Sci (Lond) 1991;81:551-556.[Medline] [Order article via Infotrieve]
  3. Ichinohe A, Kanaumi T, Takashima S, Enokido Y, Nagai Y, Kimura H. Cystathionine ß-synthase is enriched in the brains of Down’s patients. Biochem Biophys Res Commun 2005;338:1547-1550.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  4. Spector R, Coakley G, Blakely R. Methionine recycling in brain: a role for folates and vitamin B-12. J Neurochem 1980;34:132-137.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  5. Bottiglieri T, Laundy M, Martin R, Carney MW, Nissenbaum H, Toone BK, et al. S-Adenosylmethionine influences monoamine metabolism. Lancet 1984;2:224.[Web of Science][Medline] [Order article via Infotrieve]
  6. Reynolds EH, Carney MW, Toone BK. Methylation and mood. Lancet 1984;2:196-198.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  7. Garcia A, Zanibbi K. Homocysteine and cognitive function in elderly people. CMAJ 2004;171:897-904.[Abstract/Free Full Text]
  8. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005;82:636-643.[Abstract/Free Full Text]
  9. Mulder C, Schoonenboom NS, Jansen EE, Verhoeven NM, van Kamp GJ, Jakobs C, et al. The transmethylation cycle in the brain of Alzheimer patients. Neurosci Lett 2005;386:69-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  10. Obeid R, Schorr H, Eckert R, Herrmann W. Vitamin B12 status in the elderly as judged by available biochemical markers. Clin Chem 2004;50:238-241.[Free Full Text]
  11. Stabler SP, Lindenbaum J, Allen RH. Vitamin B-12 deficiency in the elderly: current dilemmas. Am J Clin Nutr 1997;66:741-749.[Abstract/Free Full Text]
  12. Hultberg B, Isaksson A, Nilsson K, Gustafson L. Markers for the functional availability of cobalamin/folate and their association with neuropsychiatric symptoms in the elderly. Int J Geriatr Psychiatry 2001;16:873-878.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  13. Nurk E, Refsum H, Tell GS, Engedal K, Vollset SE, Ueland PM, et al. Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study. Ann Neurol 2005;58:847-857.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  14. McCaddon A. Homocysteine and cognitive impairment: a case series in a General Practice setting. Nutr J 2006;5:6.[CrossRef][Medline] [Order article via Infotrieve]
  15. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006;354:2764-2772.[Abstract/Free Full Text]
  16. Clarke R, Harrison G, Richards S. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med 2003;254:67-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  17. Obeid R, Kuhlmann MK, Kohler H, Herrmann W. Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients. Clin Chem 2005;51:196-201.[Abstract/Free Full Text]
  18. Gellekink H, van Oppenraaij-Emmerzaal D, van Rooij A, Struys EA, den Heijer M, Blom HJ. Stable-isotope dilution liquid chromatography-electrospray injection tandem mass spectrometry method for fast, selective measurement of S-adenosylmethionine and S-adenosylhomocysteine in plasma. Clin Chem 2005;51:1487-1492.[Abstract/Free Full Text]
  19. Regland B, Abrahamsson L, Blennow K, Grenfeldt B, Gottfries CG. CSF-methionine is elevated in psychotic patients. J Neural Transm 2004;111:631-640.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  20. Stabler SP, Allen RH, Barrett RE, Savage DG, Lindenbaum J. Cerebrospinal fluid methylmalonic acid levels in normal subjects and patients with cobalamin deficiency. Neurology 1991;41:1627-1632.[Abstract/Free Full Text]
  21. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease. J Neurochem 1996;67:1328-1331.[Web of Science][Medline] [Order article via Infotrieve]
  22. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53:1096-1098.[Abstract/Free Full Text]
  23. Vrethem M, Mattsson E, Hebelka H, Leerbeck K, Osterberg A, Landtblom AM, et al. Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid. Mult Scler 2003;9:239-245.[Abstract/Free Full Text]
  24. Surtees R, Bowron A, Leonard J. Cerebrospinal fluid and plasma total homocysteine and related metabolites in children with cystathionine ß-synthase deficiency: the effect of treatment. Pediatr Res 1997;42:577-582.[Web of Science][Medline] [Order article via Infotrieve]
  25. Ramaekers VT, Hansen SI, Holm J, Opladen T, Senderek J, Hausler M, et al. Reduced folate transport to the CNS in female Rett patients. Neurology 2003;61:506-515.[Abstract/Free Full Text]
  26. Alperin JB, Haggard ME. Cerebrospinal fluid folate (CFA) and the blood brain barrier. Clin Res 1970;18:40.
  27. Reynolds EH. Folic acid, ageing, depression, and dementia. BMJ 2002;324:1512-1515.[Free Full Text]
  28. Botez MI, Young SN, Bachevalier J, Gauthier S. Folate deficiency and decreased brain 5-hydroxytryptamine synthesis in man and rat. Nature 1979;278:182-183.[CrossRef][Medline] [Order article via Infotrieve]
  29. Quinn CT, Griener JC, Bottiglieri T, Arning E, Winick NJ. Effects of intraventricular methotrexate on folate, adenosine, and homocysteine metabolism in cerebrospinal fluid. J Pediatr Hematol Oncol 2004;26:386-388.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  30. Serot JM, Barbe F, Arning E, Bottiglieri T, Franck P, Montagne P, et al. Homocysteine and methylmalonic acid concentrations in cerebrospinal fluid: relation with age and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2005;76:1585-1587.[Abstract/Free Full Text]
  31. Bottiglieri T, Reynolds EH, Laundy M. Folate in CSF and age. J Neurol Neurosurg Psychiatry 2000;69:562.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  32. Lazar GS, Carmel R. Cobalamin binding and uptake in vitro in the human central nervous system. J Lab Clin Med 1981;97:123-133.[Web of Science][Medline] [Order article via Infotrieve]
  33. Begley JA, Colligan PD, Chu RC. Synthesis and secretion of transcobalamin II by cultured astrocytes derived from human brain tissue. J Neurol Sci 1994;122:57-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  34. Nijst TQ, Wevers RA, Schoonderwaldt HC, Hommes OR, de Haan AF. Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psychiatry 1990;53:951-954.[Abstract/Free Full Text]
  35. Frenkel EP, McCall MS, White JD. An isotopic measurement of vitamin B12 in cerebrospinal fluid. Am J Clin Pathol 1971;55:58-64.[Web of Science][Medline] [Order article via Infotrieve]
  36. Brosnan JT, Brosnan ME. Branched-chain amino acids: enzyme and substrate regulation. J Nutr 2006;136(Suppl):207S-211S.[Abstract/Free Full Text]
  37. Silverberg GD, Heit G, Huhn S, Jaffe RA, Chang SD, Bronte-Stewart H, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer’s type. Neurology 2001;57:1763-1766.[Abstract/Free Full Text]
  38. Weir DG, Molloy AM, Keating JN, Young PB, Kennedy S, Kennedy DG, et al. Correlation of the ratio of S-adenosyl-L-methionine to S-adenosyl-L-homocysteine in the brain and cerebrospinal fluid of the pig: implications for the determination of this methylation ratio in human brain. Clin Sci (Lond) 1992;82:93-97.[Medline] [Order article via Infotrieve]
  39. Stabler SP, Allen RH. Quantification of serum and urinary S-adenosylmethionine and S-adenosylhomocysteine by stable-isotope-dilution liquid chromatography-mass spectrometry. Clin Chem 2004;50:365-372.[Abstract/Free Full Text]
  40. Baric I, Fumic K, Glenn B, Cuk M, Schulze A, Finkelstein JD, et al. S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism. Proc Natl Acad Sci U S A 2004;101:4234-4239.[Abstract/Free Full Text]



The following articles in journals at HighWire Press have cited this article:


Home page
 JAMAHome page
P. S. Aisen, L. S. Schneider, and M. Sano
High-Dose B Vitamin Supplements and Alzheimer Disease--Reply
JAMA, March 11, 2009; 301(10): 1021 - 1022.
[Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
C. Wagner and M. J Koury
S-Adenosylhomocysteine a better indicator of vascular disease than homocysteine?
Am. J. Clinical Nutrition, December 1, 2007; 86(6): 1581 - 1585.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Obeid, M. Kasoha, J.-P. Knapp, P. Kostopoulos, G. Becker, K. Fassbender, and W. Herrmann
Folate and Methylation Status in Relation to Phosphorylated Tau Protein(181P) and {beta}-Amyloid(1-42) in Cerebrospinal Fluid
Clin. Chem., June 1, 2007; 53(6): 1129 - 1136.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow 076448.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.076448v1
53/2/326    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Obeid, R.
Right arrow Articles by Herrmann, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Obeid, R.
Right arrow Articles by Herrmann, W.
Related Collections
Right arrow General Clinical Chemistry

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS